世界の経皮ドラッグデリバリーシステム市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV04883)
◆英語タイトル:Global Transdermal Drug Delivery Systems Market Size, Status and Forecast 2020-2026
◆商品コード:QYR20NV04883
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2024年版があります。お問い合わせください。)
◆ページ数:126
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療、製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートは経皮ドラッグデリバリーシステムの世界市場について調査・分析した資料です。種類別(フェンタニル、ニトログリセリン、エストラジオール、ニコチン、その他)の市場規模、用途別(OTC、Rx)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別経皮ドラッグデリバリーシステムの競争状況、市場シェア
・世界の経皮ドラッグデリバリーシステム市場:種類別市場規模 2015年-2020年(フェンタニル、ニトログリセリン、エストラジオール、ニコチン、その他)
・世界の経皮ドラッグデリバリーシステム市場:種類別市場規模予測 2021年-2026年(フェンタニル、ニトログリセリン、エストラジオール、ニコチン、その他)
・世界の経皮ドラッグデリバリーシステム市場:用途別市場規模 2015年-2020年(OTC、Rx)
・世界の経皮ドラッグデリバリーシステム市場:用途別市場規模予測 2021年-2026年(OTC、Rx)
・北米の経皮ドラッグデリバリーシステム市場分析:米国、カナダ
・ヨーロッパの経皮ドラッグデリバリーシステム市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの経皮ドラッグデリバリーシステム市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の経皮ドラッグデリバリーシステム市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの経皮ドラッグデリバリーシステム市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Hisamitsu、Mylan、GSK、Novartis、Teve(Actavis)、Johnson & Johnson、UCB、Teikoku Seiyaku、Bayer、Lingrui、Sanofi、Qizheng、Endo、Huarun 999、Haw Par、Nichiban、Mentholatum Company、Laboratoires Genevrier
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Transdermal Drug Delivery System is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive.

Market Analysis and Insights: Global Transdermal Drug Delivery Systems Market
The global Transdermal Drug Delivery Systems market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Transdermal Drug Delivery Systems Scope and Market Size
Transdermal Drug Delivery Systems market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Transdermal Drug Delivery Systems market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Hisamitsu
Mylan
GSK
Novartis
Teve(Actavis)
Johnson & Johnson
UCB
Teikoku Seiyaku
Bayer
Lingrui
Sanofi
Qizheng
Endo
Huarun 999
Haw Par
Nichiban
Mentholatum Company
Laboratoires Genevrier

Market segment by Type, the product can be split into
Fentanyl
Nitroglycerin
Estradiol
Nicotine
Other
Market segment by Application, split into
OTC
Rx

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Transdermal Drug Delivery Systems Revenue
1.4 Market by Type
1.4.1 Global Transdermal Drug Delivery Systems Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Fentanyl
1.4.3 Nitroglycerin
1.4.4 Estradiol
1.4.5 Nicotine
1.4.6 Other
1.5 Market by Application
1.5.1 Global Transdermal Drug Delivery Systems Market Share by Application: 2020 VS 2026
1.5.2 OTC
1.5.3 Rx
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Transdermal Drug Delivery Systems Market Perspective (2015-2026)
2.2 Global Transdermal Drug Delivery Systems Growth Trends by Regions
2.2.1 Transdermal Drug Delivery Systems Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Transdermal Drug Delivery Systems Historic Market Share by Regions (2015-2020)
2.2.3 Transdermal Drug Delivery Systems Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Transdermal Drug Delivery Systems Market Growth Strategy
2.3.6 Primary Interviews with Key Transdermal Drug Delivery Systems Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Transdermal Drug Delivery Systems Players by Market Size
3.1.1 Global Top Transdermal Drug Delivery Systems Players by Revenue (2015-2020)
3.1.2 Global Transdermal Drug Delivery Systems Revenue Market Share by Players (2015-2020)
3.1.3 Global Transdermal Drug Delivery Systems Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Transdermal Drug Delivery Systems Market Concentration Ratio
3.2.1 Global Transdermal Drug Delivery Systems Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Transdermal Drug Delivery Systems Revenue in 2019
3.3 Transdermal Drug Delivery Systems Key Players Head office and Area Served
3.4 Key Players Transdermal Drug Delivery Systems Product Solution and Service
3.5 Date of Enter into Transdermal Drug Delivery Systems Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Transdermal Drug Delivery Systems Historic Market Size by Type (2015-2020)
4.2 Global Transdermal Drug Delivery Systems Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Transdermal Drug Delivery Systems Market Size by Application (2015-2020)
5.2 Global Transdermal Drug Delivery Systems Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Transdermal Drug Delivery Systems Market Size (2015-2020)
6.2 Transdermal Drug Delivery Systems Key Players in North America (2019-2020)
6.3 North America Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
6.4 North America Transdermal Drug Delivery Systems Market Size by Application (2015-2020)

7 Europe
7.1 Europe Transdermal Drug Delivery Systems Market Size (2015-2020)
7.2 Transdermal Drug Delivery Systems Key Players in Europe (2019-2020)
7.3 Europe Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
7.4 Europe Transdermal Drug Delivery Systems Market Size by Application (2015-2020)

8 China
8.1 China Transdermal Drug Delivery Systems Market Size (2015-2020)
8.2 Transdermal Drug Delivery Systems Key Players in China (2019-2020)
8.3 China Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
8.4 China Transdermal Drug Delivery Systems Market Size by Application (2015-2020)

9 Japan
9.1 Japan Transdermal Drug Delivery Systems Market Size (2015-2020)
9.2 Transdermal Drug Delivery Systems Key Players in Japan (2019-2020)
9.3 Japan Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
9.4 Japan Transdermal Drug Delivery Systems Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Transdermal Drug Delivery Systems Market Size (2015-2020)
10.2 Transdermal Drug Delivery Systems Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
10.4 Southeast Asia Transdermal Drug Delivery Systems Market Size by Application (2015-2020)

11 India
11.1 India Transdermal Drug Delivery Systems Market Size (2015-2020)
11.2 Transdermal Drug Delivery Systems Key Players in India (2019-2020)
11.3 India Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
11.4 India Transdermal Drug Delivery Systems Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Transdermal Drug Delivery Systems Market Size (2015-2020)
12.2 Transdermal Drug Delivery Systems Key Players in Central & South America (2019-2020)
12.3 Central & South America Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
12.4 Central & South America Transdermal Drug Delivery Systems Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Hisamitsu
13.1.1 Hisamitsu Company Details
13.1.2 Hisamitsu Business Overview
13.1.3 Hisamitsu Transdermal Drug Delivery Systems Introduction
13.1.4 Hisamitsu Revenue in Transdermal Drug Delivery Systems Business (2015-2020))
13.1.5 Hisamitsu Recent Development
13.2 Mylan
13.2.1 Mylan Company Details
13.2.2 Mylan Business Overview
13.2.3 Mylan Transdermal Drug Delivery Systems Introduction
13.2.4 Mylan Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
13.2.5 Mylan Recent Development
13.3 GSK
13.3.1 GSK Company Details
13.3.2 GSK Business Overview
13.3.3 GSK Transdermal Drug Delivery Systems Introduction
13.3.4 GSK Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
13.3.5 GSK Recent Development
13.4 Novartis
13.4.1 Novartis Company Details
13.4.2 Novartis Business Overview
13.4.3 Novartis Transdermal Drug Delivery Systems Introduction
13.4.4 Novartis Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
13.4.5 Novartis Recent Development
13.5 Teve(Actavis)
13.5.1 Teve(Actavis) Company Details
13.5.2 Teve(Actavis) Business Overview
13.5.3 Teve(Actavis) Transdermal Drug Delivery Systems Introduction
13.5.4 Teve(Actavis) Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
13.5.5 Teve(Actavis) Recent Development
13.6 Johnson & Johnson
13.6.1 Johnson & Johnson Company Details
13.6.2 Johnson & Johnson Business Overview
13.6.3 Johnson & Johnson Transdermal Drug Delivery Systems Introduction
13.6.4 Johnson & Johnson Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
13.6.5 Johnson & Johnson Recent Development
13.7 UCB
13.7.1 UCB Company Details
13.7.2 UCB Business Overview
13.7.3 UCB Transdermal Drug Delivery Systems Introduction
13.7.4 UCB Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
13.7.5 UCB Recent Development
13.8 Teikoku Seiyaku
13.8.1 Teikoku Seiyaku Company Details
13.8.2 Teikoku Seiyaku Business Overview
13.8.3 Teikoku Seiyaku Transdermal Drug Delivery Systems Introduction
13.8.4 Teikoku Seiyaku Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
13.8.5 Teikoku Seiyaku Recent Development
13.9 Bayer
13.9.1 Bayer Company Details
13.9.2 Bayer Business Overview
13.9.3 Bayer Transdermal Drug Delivery Systems Introduction
13.9.4 Bayer Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
13.9.5 Bayer Recent Development
13.10 Lingrui
13.10.1 Lingrui Company Details
13.10.2 Lingrui Business Overview
13.10.3 Lingrui Transdermal Drug Delivery Systems Introduction
13.10.4 Lingrui Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
13.10.5 Lingrui Recent Development
13.11 Sanofi
10.11.1 Sanofi Company Details
10.11.2 Sanofi Business Overview
10.11.3 Sanofi Transdermal Drug Delivery Systems Introduction
10.11.4 Sanofi Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
10.11.5 Sanofi Recent Development
13.12 Qizheng
10.12.1 Qizheng Company Details
10.12.2 Qizheng Business Overview
10.12.3 Qizheng Transdermal Drug Delivery Systems Introduction
10.12.4 Qizheng Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
10.12.5 Qizheng Recent Development
13.13 Endo
10.13.1 Endo Company Details
10.13.2 Endo Business Overview
10.13.3 Endo Transdermal Drug Delivery Systems Introduction
10.13.4 Endo Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
10.13.5 Endo Recent Development
13.14 Huarun 999
10.14.1 Huarun 999 Company Details
10.14.2 Huarun 999 Business Overview
10.14.3 Huarun 999 Transdermal Drug Delivery Systems Introduction
10.14.4 Huarun 999 Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
10.14.5 Huarun 999 Recent Development
13.15 Haw Par
10.15.1 Haw Par Company Details
10.15.2 Haw Par Business Overview
10.15.3 Haw Par Transdermal Drug Delivery Systems Introduction
10.15.4 Haw Par Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
10.15.5 Haw Par Recent Development
13.16 Nichiban
10.16.1 Nichiban Company Details
10.16.2 Nichiban Business Overview
10.16.3 Nichiban Transdermal Drug Delivery Systems Introduction
10.16.4 Nichiban Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
10.16.5 Nichiban Recent Development
13.17 Mentholatum Company
10.17.1 Mentholatum Company Company Details
10.17.2 Mentholatum Company Business Overview
10.17.3 Mentholatum Company Transdermal Drug Delivery Systems Introduction
10.17.4 Mentholatum Company Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
10.17.5 Mentholatum Company Recent Development
13.18 Laboratoires Genevrier
10.18.1 Laboratoires Genevrier Company Details
10.18.2 Laboratoires Genevrier Business Overview
10.18.3 Laboratoires Genevrier Transdermal Drug Delivery Systems Introduction
10.18.4 Laboratoires Genevrier Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
10.18.5 Laboratoires Genevrier Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

...

【掲載企業】

Hisamitsu、Mylan、GSK、Novartis、Teve(Actavis)、Johnson & Johnson、UCB、Teikoku Seiyaku、Bayer、Lingrui、Sanofi、Qizheng、Endo、Huarun 999、Haw Par、Nichiban、Mentholatum Company、Laboratoires Genevrier

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の経皮ドラッグデリバリーシステム市場2026:インサイト・予測(Global Transdermal Drug Delivery Systems Market Size, Status and Forecast 2020-2026)]についてメールでお問い合わせはこちらでお願いします。